Rep. Thomas H. Kean, Jr. Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on September 30th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Johnson & Johnson Trading Down 0.1%

Shares of NYSE JNJ traded down $0.38 during midday trading on Tuesday, reaching $270.18. 1,093,810 shares of the stock were exchanged, compared to its average volume of 7,928,009. The business has a 50-day simple moving average of $265.74 and a two-hundred day simple moving average of $247.22. The company has a market capitalization of $650.41 billion, a price-to-earnings ratio of 41.02, a P/E/G ratio of 2.68 and a beta of 0.22. Johnson & Johnson has a 12 month low of $185.12 and a 12 month high of $282.02. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the business earned $2.80 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Real-world registry data presented at the TCT 2026 symposium showed lower in-hospital and short-term mortality for patients undergoing high-risk percutaneous coronary intervention with Impella support. The analysis covered 1,379 patients at U.S. and European centers, providing additional support for adoption of the device. Johnson & Johnson reports lower mortality rates in Impella-supported high-risk coronary procedures
• Positive Sentiment: A separate report highlighted a 94% success rate in a coronary-device trial. While further clinical evidence is still expected from the ongoing PROTECT IV study, the results could support Impella’s clinical credibility and commercial growth. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, indicating institutional demand that may provide support for the stock. ETFs Are Buying Johnson & Johnson (JNJ) on Oct. 29
• Neutral Sentiment: Analysts continue to view JNJ as a high-quality healthcare and dividend company, with streamlining efforts and a durable payout supporting its defensive investment case. The Best Dividend Stocks to Buy With $5,000 in November
• Negative Sentiment: Despite the favorable Impella news, commentary questions whether JNJ is fully valued after substantial recent gains, raising the risk that positive clinical developments are already reflected in the share price. Johnson & Johnson (JNJ) As Impella Data Fuels The Story, Is The Stock Fully Valued?

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Evercore set a $300.00 price target on Johnson & Johnson in a research report on Tuesday, October 20th. TD Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $28,000. Matrix Trust Co lifted its stake in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $43,000. Hanseatic Management Services Inc. acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $52,000. Finally, Polaris Financial Partners acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $56,000. 69.55% of the stock is owned by institutional investors and hedge funds.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.